1 Title

2 No association between circulating levels of testosterone and sex
3 hormone-binding globulin and risk of COVID-19 mortality in UK biobank

4

5 Authors

6 Xikang Fan^{1 *}, Jing Yang^{1 *}, Jiayu Wang¹, Cheng Yin², Meng Zhu¹, Hongxia
7 Ma^{1,3,4}, Guangfu Jin^{1,3,4}, Zhibin Hu^{1,3,4}, Hongbing Shen^{1,4}, Dong Hang^{1,4}

8

9 * Co-first authors, contributed equally.

10

11 Affiliations

12 ¹ Department of Epidemiology and Biostatistics, International Joint Research
13 Center on Environment and Human Health, Center for Global Health, School
14 of Public Health, Nanjing Medical University, Nanjing, China, 211166;

15 ² Department of Laboratory, Jiangning Hospital Affiliated to Nanjing Medical
16 University, Nanjing, China, 211100;

17 ³ State Key Laboratory of Reproductive Medicine, Center for Global Health,
18 Nanjing Medical University, Nanjing, China, 211166;

19 ⁴ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment,
20 Collaborative Innovation Center for Cancer Medicine, Nanjing Medical
21 University, Nanjing, China, 211166.

22

23 **Short title:** sex hormone and COVID-19 mortality

24

25 **Correspondence:**

26 Dong Hang, PhD

27 Department of Epidemiology and Biostatistics, School of Public Health,

28 Nanjing Medical University, 101 Longmian Avenue, Nanjing 211166, China.

29 Email: hangdong@njmu.edu.cn

30

31 **Funding**

32 This study was funded by National Natural Science Foundation of China

33 (81820108028, 81521004, and 81973127), National Key R&D Program of

34 China (2016YFC1000200 and 2017YFC0908300), and Science Foundation for

35 Excellent Young Scholars of Jiangsu (BK20190083). The funders had no role

36 in study design, data collection and analysis, decision to publish, or

37 preparation of the manuscript.

38

39 **Disclosure Summary:** The authors have nothing to disclose.

40

41 **Abbreviations**

42 COVID-19: coronavirus disease 2019; SHBG: sex hormone-binding globulin;

43 FT: free testosterone; TT: total testosterone; SARS-CoV-2: severe acute

44 respiratory syndrome coronavirus 2; NHS: National Health Service; BMI: body

45 mass index; MET, metabolic equivalent; ICD: international classification of

46 diseases; HRT: hormone replacement treatment; OR: odds ratio; CI:

47 confidence interval; SD: standard deviation.

48 **Abstract**

49 **Background:** Sex-disaggregated data suggest that men with coronavirus
50 disease 2019 (COVID-19) are more likely to die than women. Whether
51 circulating testosterone or sex hormone-binding globulin (SHBG) contributes
52 to such sex differences remains unknown.

53 **Objective:** To evaluate the associations of circulating total testosterone (TT),
54 free testosterone (FT), and SHBG with COVID-19 mortality.

55 **Design:** Prospective analysis.

56 **Setting:** UK Biobank.

57 **Participants:** We included 1306 COVID-19 patients (678 men and 628
58 women) who had serum TT and SHBG measurements and were free of
59 cardiovascular disease or cancer at baseline (2006-2010).

60 **Main outcome measures:** The death cases of COVID-19 were identified from
61 National Health Service death records updated at 31 July 2020. Unconditional
62 logistic regression was performed to estimate the odds ratio (OR) and 95%
63 confidence intervals (CI) for mortality.

64 **Results:** We documented 315 deaths of COVID-19 (194 men and 121
65 women). After adjusting for potential confounders, we did not find any
66 statistically significant associations for TT (OR per 1-SD increase = 1.03, 95%
67 CI: 0.85-1.25), FT (OR per 1-SD increase = 0.95, 95% CI: 0.77-1.17), or SHBG
68 (OR per 1-SD increase = 1.09, 95% CI: 0.87-1.37) with COVID-19 mortality in
69 men. Similar null results were observed in women (TT: OR per 1-SD increase

70 = 1.10, 95% CI: 0.85-1.42; FT: OR per 1-SD increase = 1.10, 95% CI:

71 0.82-1.46; SHBG: OR per 1-SD increase = 1.16, 95% CI: 0.89-1.53).

72 **Conclusions:** Our findings do not support a significant role of circulating

73 testosterone or SHBG in COVID-19 prognosis.

74

75 **Keywords:** testosterone, sex hormone, COVID-19, mortality, UK Biobank

76 Introduction

77 The coronavirus disease 2019 (COVID-19) pandemic is a global health
78 emergency that has led to more than 870,000 deaths worldwide
79 (<https://covid19.who.int/>). According to sex-disaggregated data from many
80 affected countries, there seem to be sex differences in severity and mortality of
81 the disease (1-3). Men with COVID-19 are more likely to need intensive care
82 and to die than women, with an overall case-fatality ratio of approximately 1.7
83 (4). Several hypotheses have been proposed to account for the difference,
84 such as smoking, co-morbid conditions, immune responses, and sex
85 hormones (4, 5). As the most abundant circulating androgen in men,
86 testosterone has been suggested as an immunosuppressive factor by
87 inhibiting B lymphopoiesis, T-helper 1 differentiation, and inflammatory
88 cytokine production (6, 7). However, epidemiologic data are sparse regarding
89 the association between circulating testosterone levels and COVID-19
90 prognosis in either men or women.

91 Most circulating testosterone is tightly bound to sex hormone-binding
92 globulin (SHBG) or weakly bound to albumin, and a minor amount exists as
93 free testosterone (FT) (8). In the current study, we leveraged the UK Biobank
94 resource, with recently released data on COVID-19 tests and updated death
95 records, to examine the associations of total testosterone (TT), calculated FT,
96 and SHBG with mortality among COVID-19 patients.

97

98 **Methods**

99 **Study design and participants**

100 UK Biobank enrolled over 500,000 community-dwelling individuals (aged
101 37-73 years) across the UK during 2006 to 2010 (9). At the baseline
102 assessment, participants completed self-administered touchscreen
103 questionnaires, had physical measurements by qualified nurses, and provided
104 blood samples.

105 According to the Public Health England database linked to UK biobank
106 updated at 3 August 2020, a total of 9773 participants had undergone severe
107 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests, among whom
108 1638 were diagnosed with COVID-19. We also included 161 participants who
109 died from COVID-19 according to the National Health Service (NHS) death
110 records. Exclusion criteria included COVID-19 patients who had no available
111 data on serum TT (n=286) or SHBG (n=309), who had a self-reported history
112 of cardiovascular disease (n=176) or cancer (n=138) at blood draw, and who
113 died from other causes (n=22). Finally, 1306 patients with COVID-19 were
114 included in the analysis, consisting of 678 men and 628 women.

115

116 **Assessment of biomarkers**

117 Serum concentrations of TT and SHBG were measured by chemiluminescent
118 immunoassays (Beckman Coulter DXI 800), with analytical ranges of
119 0.35-55.52 nmol/L and 0.33-242 nmol/L, respectively. A colorimetric method

120 was used to assay albumin (Beckman Coulter AU5800), with an analytical
121 range of 15-60 g/L. Overall, the average coefficients of variation for TT, SHBG,
122 and albumin ranged from 3.66-8.34%, 5.22-5.67%, and 2.09-2.20%,
123 respectively. Moreover, each assay was registered with an external quality
124 assurance scheme to verify the accuracy, showing that more than 95% of
125 participated distributions for these biomarkers were good or acceptable. FT
126 was calculated using a validated algorithm based on TT, SHBG, albumin, and
127 the association constants for the binding of testosterone to SHBG and albumin
128 (10, 11)

129

130 **Ascertainment of COVID-19 Mortality**

131 Date and cause of death were obtained through linkage to national death
132 registries. Primary cause of mortality was defined using the 10th revision of the
133 International Statistical Classification of Diseases, and the outcome of our
134 analysis was mortality due to COVID-19 (U07). Available death data we used
135 were last updated at 31 July 2020.

136

137 **Ascertainment of Covariates**

138 Information on age, sex, education, ethnicity, smoking status, and alcohol
139 consumption was self-reported in the baseline questionnaires. Townsend
140 deprivation index was evaluated by incorporating measures of unemployment,
141 household overcrowding, and non-ownership of home or car. Body mass index

(BMI) was calculated as weight in kilograms divided by height in meters squared derived from physical measurements. Total physical activity was assessed by total metabolic equivalent task minutes per week for all activity, including walking, moderate, and vigorous activity.

146

147 **Statistical Analysis**

148 Testosterone and SHBG concentrations were log-transformed to improve
149 normality. Because the date of SARS-CoV-2 testing did not represent the date
150 of getting infected, the survival time from infection to death or the last follow-up
151 could not be accurately calculated for each patient, rendering Cox regression
152 models inapplicable in the current analysis. We used unconditional logistic
153 regression models to estimate odds ratios (OR) and 95% confidence intervals
154 (CI), according to quintiles and continuously per 1-standard deviation (SD)
155 increment in hormone concentrations. The model was first adjusted for major
156 covariates including age at infection, sex, and ethnicity (simple model), then
157 further adjusted for Townsend deprivation index, BMI, smoking status, alcohol
158 drinking, physical activity, and for women, menopause status and hormone
159 replacement treatment (HRT) (full model).

160 Stratified analyses were conducted according to the median age at
161 infection (<70, ≥70 years), sex (male, female), BMI (<30, ≥30 kg/m²), physical
162 activity (≤median, >median), and smoking status (never, ever) in the full
163 models. To estimate potential effect modification by these stratification

164 variables, we used a likelihood ratio test comparing the models with and
165 without interaction terms between hormone levels and each stratification
166 variable. In addition, sensitivity analysis was performed by excluding
167 participants with self-rated poor overall health at baseline.

168 All analyses were performed with SAS 9.4. Statistical tests were all
169 two-sided, and $P < 0.05$ was regarded as statistically significant.

170

171 Results

172 Among 678 male and 628 female patients with COVID-19, 194 (28.6%) and
173 121 (19.3%) deaths occurred, respectively. The median time from blood draw
174 to COVID-19 testing was 11.1 years (interquartile range: 10.5-11.9 years). TT
175 concentrations ranged from 1.96-27.45 nmol/L in men and 0.35-4.44 nmol/L in
176 women (**Figure S1**). SHBG concentrations ranged from 2.59-133.66 nmol/L in
177 men and 10.15-218.89 nmol/L in women.

178 **Table 1** summarizes the main characteristics of COVID-19 patients by
179 quartiles of TT levels. FT and SHBG levels increased with TT levels. Moreover,
180 patients with higher TT tended to be younger at blood draw. Men with higher
181 BMI and women using HRT were more likely to have lower TT levels.

182 **Tables 2 and 3** showed the association results for the hormones and
183 COVID-19 mortality in men and women, respectively. We did not find any
184 statistically significant associations for TT (fully adjusted OR per 1-SD increase
185 = 1.03, 95% CI: 0.85-1.25), FT (fully adjusted OR per 1-SD increase = 0.95, 95%

186 CI: 0.77-1.17), or SHBG (fully adjusted OR per 1-SD increase = 1.09, 95% CI:
187 0.87-1.37) with COVID-19 mortality in men. Similar null results were observed
188 in women (TT: fully adjusted OR per 1-SD increase = 1.10, 95% CI: 0.85-1.42;
189 FT: fully adjusted OR per 1-SD increase = 1.10, 95% CI: 0.82-1.46; SHBG:
190 fully adjusted OR per 1-SD increase = 1.16, 95% CI: 0.89-1.53).

191 The forest plot of stratified analyses (**Figure 1**) showed that none of the
192 stratification variables had modification effects on TT, FT, and SHBG levels in
193 men and women.

194 The sensitivity analysis also indicated that the hormones were not
195 associated with COVID-19 mortality (**Tables S1 and S2**).

196

197 Discussion

198 To the best of our knowledge, this is the first study to assess the association of
199 pre-diagnostic testosterone and SHBG levels with COVID-19 mortality. We did
200 not observe any statistically significant associations in either men (n=678) or
201 women (n=628), suggesting that circulating testosterone and SHBG may not
202 play a critical role in COVID-19 prognosis.

203 In support of our findings, a prior study of 543 male patients with
204 COVID-19 from UK Biobank did not identify any significant associations for
205 baseline TT and SHBG levels with an increased risk of SARS-CoV-2 infection
206 or hospitalization (12). However, in another study of 31 male patients with
207 COVID-19 in Italy, lower TT and FT levels were associated with a higher risk of

208 clinical deterioration (intensive care unit transfer or death) (13). Meanwhile,
209 another study of 221 male patients reported that those who died from
210 COVID-19 had lower mean TT levels than the patients alive (14). These two
211 smaller studies were limited by inadequate adjustment for confounders, and
212 they measured testosterone when patients were already hospitalized with
213 COVID-19, which could introduce reverse causation.

214 The proposed leading cause of COVID-19 deterioration is the intense
215 inflammatory response, known as a cytokine storm, which severely damages
216 the lung tissue and causes acute respiratory distress syndrome (15). Sex
217 differences in the response to inflammation have been well documented and
218 can be attributed to various factors including sex hormones (16, 17). The
219 current study suggests that circulating testosterone and SHBG may not be
220 implicated in COVID-19 prognosis. However, we were unable to evaluate the
221 association between estrogens and COVID-19 mortality because the majority
222 of estradiol measurements were below the limit of detection in UK biobank. In
223 a published cross-sectional study, serum estradiol showed negative
224 correlations with severity of COVID-19 and levels of cytokines related to
225 inflammation (18). Animal experiments also showed that estrogen signaling
226 could suppress the inflammatory reactions and decrease severe acute
227 respiratory syndrome coronavirus titers, leading to improved survival, while
228 androgens did not influence disease outcome in male mice (19). Therefore,
229 further studies are warranted to clarify whether and how estrogens have a

230 beneficial effect on COVID-19 prognosis.

231 The major strengths of our study include the prospective design, reliable
232 data on hormone levels and COVID-19, detailed data on covariates that
233 allowed for robust confounding control, and evaluation of the associations both
234 in men and women separately. However, two major limitations should be
235 acknowledged. First, baseline hormones were assessed only one time, which
236 may not reflect a long-time exposure. However, the intraclass correlation
237 coefficients of TT and SHBG between two measurements (4 years apart in UK
238 biobank) were 0.59 (95% CI: 0.58-0.61) and 0.86 (95% CI: 0.86-0.87),
239 respectively, in men; 0.63 (95% CI: 0.62-0.64) and 0.81 (95% CI: 0.80-0.82),
240 respectively, in women, indicating that a single measurement can reliably
241 categorize average levels over at least a 4-year period (20). Second, limited by
242 the coverage of COVID-19 testing, ascertainment bias may have occurred in
243 the current study.

244

245 **Conclusions**

246 Our findings indicate that circulating levels of testosterone and SHBG are not
247 associated with COVID-19 prognosis. Future studies may focus on other
248 factors to unravel the mechanisms underlying sex differences in COVID-19
249 mortality.

250

251 **Acknowledgments**

252 We are grateful to UK Biobank participants. This research has been conducted
253 using the UK Biobank resource under application number 52217.

254

255 **Author Contributions**

256 DH was responsible for the conception and design of the study. XF and DH
257 had full access to all the data in the study and took responsibility for the
258 integrity of the data and the accuracy of the data analysis. XF and JY did the
259 statistical analysis and drafted the manuscript. JW, CY, MZ, HM, GJ, ZH, and
260 HS critically revised the manuscript for important intellectual content. All
261 authors reviewed and approved the final manuscript.

262

263 **References**

- 264 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
265 patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*.
266 2020;395(10223):497-506.
- 267 2. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy.
268 *Jama*. 2020.
- 269 3. Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis
270 F. Biological sex impacts COVID-19 outcomes. *PLoS Pathog*.
271 2020;16(6):e1008570.
- 272 4. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering
273 how biological sex impacts immune responses and COVID-19 outcomes. *Nat*

- 274 Rev Immunol. 2020;20(7):442-7.
- 275 5. Chakravarty D, Nair SS, Hammouda N, Ratnani P, Gharib Y, Wagaskar V,
276 et al. Sex differences in SARS-CoV-2 infection rates and the potential link to
277 prostate cancer. Commun Biol. 2020;3(1):374.
- 278 6. Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on
279 the immune system. Cell Immunol. 2015;294(2):87-94.
- 280 7. Gubbels Bupp MR, Jorgensen TN. Androgen-Induced
281 Immunosuppression. Front Immunol. 2018;9:794.
- 282 8. Raverot V, Lopez J, Grenot C, Pugeat M, Déchaud H. New approach for
283 measurement of non-SHBG-bound testosterone in human plasma. Anal Chim
284 Acta. 2010;658(1):87-90.
- 285 9. Collins R. What makes UK Biobank special? Lancet.
286 2012;379(9822):1173-4.
- 287 10. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A,
288 Akhmedkhanov A, et al. Validity of free testosterone and free estradiol
289 determinations in serum samples from postmenopausal women by theoretical
290 calculations. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1065-71.
- 291 11. Södergård R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free
292 and bound fractions of testosterone and estradiol-17 beta to human plasma
293 proteins at body temperature. J Steroid Biochem. 1982;16(6):801-10.
- 294 12. Ghazizadeh Z, Majd H, Richter M, Samuel R, Zekavat SM, Asgharian H, et
295 al. Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with

296 Severe COVID-19 Symptoms in Men. bioRxiv. 2020.

297 13. Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D, et
298 al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2
299 pneumonia patients. Andrology. 2020.

300 14. Çayan S, Uğuz M, Saylam B, Akbay E. Effect of serum total testosterone
301 and its relationship with other laboratory parameters on the prognosis of
302 coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients:
303 a cohort study. Aging Male. 2020:1-11.

304 15. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et
305 al. COVID-19: consider cytokine storm syndromes and immunosuppression.
306 Lancet. 2020;395(10229):1033-4.

307 16. Al-Lami RA, Urban RJ, Volpi E, Algburi AMA, Baillargeon J. Sex Hormones
308 and Novel Corona Virus Infectious Disease (COVID-19). Mayo Clin Proc.
309 2020;95(8):1710-4.

310 17. Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstien B. How
311 sex and age affect immune responses, susceptibility to infections, and
312 response to vaccination. Aging Cell. 2015;14(3):309-21.

313 18. Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J, et al. Potential Influence
314 of Menstrual Status and Sex Hormones on female SARS-CoV-2 Infection: A
315 Cross-sectional Study from Multicentre in Wuhan, China. Clin Infect Dis. 2020.

316 19. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK,
317 Perlman S. Sex-Based Differences in Susceptibility to Severe Acute

318 Respiratory Syndrome Coronavirus Infection. J Immunol.
319 2017;198(10):4046-53.
320 20. Dashti SG, Viallon V, Simpson JA, Karahalios A, Moreno-Betancur M,
321 English DR, et al. Explaining the link between adiposity and colorectal cancer
322 risk in men and postmenopausal women in the UK Biobank: A sequential
323 causal mediation analysis. Int J Cancer. 2020;147(7):1881-94.
324

Table 1. Baseline characteristics of COVID-19 patients according to quartiles of serum TT levels in men and women

Characteristic	Serum TT levels in men, nmol/L				Serum TT levels in women, nmol/L			
	Q1 (1.96-9.32)	Q2 (9.32-11.25)	Q3 (11.25-13.65)	Q4 (13.67-27.45)	Q1 (0.35-0.75)	Q2 (0.75-1.01)	Q3 (1.01-1.40)	Q4 (1.40-4.44)
Participants N	169	169	170	169	135	135	135	135
Age at blood draw, mean (SD), y	58.76 (8.75)	56.22 (9.14)	57.62 (8.97)	56.53 (8.99)	56.21 (9.07)	54.51 (8.84)	52.71 (9.48)	53.38 (9.65)
Age at infection, mean (SD),	69.91 (8.82)	67.43 (9.23)	68.80 (9.00)	67.65 (8.99)	67.32 (9.07)	65.61 (8.98)	63.91 (9.49)	64.70 (9.66)
White race, No. (%)	144 (85.21)	144 (85.21)	148 (87.06)	148 (87.57)	120 (88.89)	115 (85.19)	120 (88.89)	118 (87.41)
Body mass index, mean (SD), kg/m ²	30.82 (4.66)	28.68 (4.23)	28.18 (4.54)	26.79 (3.81)	29.03 (6.60)	28.15 (5.41)	27.81 (5.50)	29.19 (5.93)
Physical activity, mean (SD), MET-hours/w	46.20 (53.77)	48.93 (50.76)	47.22 (46.24)	42.82 (38.66)	42.19 (38.11)	41.68 (43.33)	42.76 (39.92)	38.48 (36.35)
Townsend deprivation index, mean (SD)	-0.11 (3.65)	-0.13 (3.39)	-0.51 (3.32)	0.03 (3.64)	-0.23 (3.55)	-0.77 (3.23)	-0.48 (3.32)	-0.65 (3.14)
Smoking status, No. (%) ^a								
Never	52 (30.77)	76 (44.97)	89 (52.35)	71 (42.01)	83 (61.48)	67 (49.63)	83 (61.48)	81 (60.00)
Previous	88 (52.07)	73 (43.20)	63 (37.06)	76 (44.97)	37 (27.41)	42 (31.11)	37 (27.41)	40 (29.63)
Current	24 (14.20)	19 (11.24)	17 (10.00)	21 (12.43)	14 (10.37)	25 (18.52)	15 (11.11)	13 (9.63)
Alcohol consumption, No. (%) ^a								
Daily to three times a week	73 (43.20)	62 (36.69)	76 (44.71)	79 (46.75)	32 (23.70)	31 (22.96)	38 (28.15)	38 (28.15)
Twice a week to once a month	61 (36.09)	67 (39.64)	62 (36.47)	60 (35.50)	58 (42.96)	54 (40.00)	57 (42.22)	58 (42.96)
Never or special	32 (18.93)	39 (23.08)	32 (18.82)	30 (17.75)	44 (32.59)	50 (37.04)	39 (28.89)	39 (28.89)

occasions only								
Had menopause, No. (%)	NA	NA	NA	NA	70 (51.85)	66 (48.89)	60 (44.44)	60 (44.44)
Ever used HRT, No. (%)	NA	NA	NA	NA	54 (40.00)	43 (31.85)	32 (23.70)	29 (21.48)
SHBG, nmol/L	27.62 (11.13)	33.30 (12.18)	39.34 (11.43)	53.17 (22.18)	57.07 (29.76)	61.39 (31.20)	63.11 (28.18)	58.97 (30.56)
FT, nmol/L	0.13 (0.03)	0.16 (0.04)	0.17 (0.04)	0.19 (0.07)	0.006 (0.002)	0.008 (0.003)	0.011 (0.004)	0.018 (0.009)

Abbreviations: TT, total testosterone; MET, metabolic equivalent; HRT, hormone-replacement therapy; NA, not applicable; SHBG, sex hormone-binding globulin; FT, free testosterone.

^a The total did not sum to 100% because small proportions of participants chose "prefer not to answer" on some questions.

Table 2. Associations of serum TT, FT, and SHBG levels with COVID-19 mortality in men

	Q1	Q2	Q3	Q4	<i>P</i> -trend	OR per 1-SD increment ^c
Quartile of serum TT levels, OR (95% CI)						
Cutpoints, nmol/L	1.96-9.32	9.32-11.25	11.25-13.65	13.67-27.45		
No. of cases	49	48	58	39		
Simple model ^a	ref	1.31 (0.78-2.21)	1.54 (0.93-2.55)	0.93 (0.54-1.58)	0.99	1.00 (0.83-1.20)
Full model ^b	ref	1.39 (0.81-2.38)	1.71 (1.00-2.93)	1.02 (0.58-1.81)	0.73	1.03 (0.85-1.25)
Quartile of FT levels, OR (95% CI)						
Cutpoints, nmol/L	0.04-0.13	0.13-0.15	0.15-0.19	0.19-0.58		
No. of cases	61	48	40	29		
Simple model ^a	ref	0.98 (0.59-1.62)	0.94 (0.55-1.60)	0.98 (0.54-1.79)	0.67	0.96 (0.78-1.17)
Full model ^b	ref	0.97 (0.58-1.63)	0.92 (0.53-1.58)	0.97 (0.53-1.78)	0.64	0.95 (0.77-1.17)
Quartile of SHBG levels, OR (95% CI)						
Cutpoints, nmol/L	2.59-25.99	26.16-35.32	35.34-46.57	46.65-133.66		
No. of cases	31	46	44	58		
Simple model ^a	ref	1.23 (0.68-2.20)	0.83 (0.46-1.49)	1.11 (0.62-1.98)	0.64	1.05 (0.85-1.30)
Full model ^b	ref	1.33 (0.73-2.44)	0.89 (0.48-1.63)	1.20 (0.65-2.22)	0.44	1.09 (0.87-1.37)

Abbreviations: TT, total testosterone; FT, free testosterone; SHBG, sex hormone-binding globulin; OR, odds ratio; CI, confidence interval; ref, reference.

^a Adjusted for age at infection, sex, and race.

^b Additionally adjusted for Townsend deprivation index, body mass index, smoking status, alcohol drinking, and physical activity.

^c SD was the standard deviation of log-transformed hormone levels: 0.31 for TT, 0.31 for FT, and 0.46 for SHBG.

Table 3. Associations of serum TT, FT, and SHBG levels with COVID-19 mortality in women

	Q1	Q2	Q3	Q4	P-trend	OR per 1-SD increment ^c
Quartile of serum TT levels, OR (95% CI)						
Cutpoints, nmol/L	0.35-0.75	0.75-1.01	1.01-1.40	1.40-4.44		
No. of cases	26	26	16	28		
Simple model ^a	ref	1.25 (0.64-2.46)	0.75 (0.35-1.57)	1.49 (0.76-2.93)	0.41	1.11 (0.87-1.42)
Full model ^b	ref	1.17 (0.57-2.39)	0.71 (0.32-1.57)	1.38 (0.68-2.81)	0.46	1.10 (0.85-1.42)
Quartile of FT levels, OR (95% CI)						
Cutpoints, nmol/L	0.002-0.006	0.006-0.009	0.009-0.013	0.013-0.070		
No. of cases	23	17	20	26		
Simple model ^a	ref	0.75 (0.36-1.59)	0.87 (0.42-1.81)	1.37 (0.67-2.80)	0.11	1.24 (0.95-1.60)
Full model ^b	ref	0.79 (0.36-1.74)	0.75 (0.35-1.63)	1.05 (0.48-2.31)	0.53	1.10 (0.82-1.46)
Quartile of SHBG levels, OR (95% CI)						
Cutpoints, nmol/L	10.15-37.58	37.63-54.35	54.42-76.08	76.98-218.89		
No. of cases	28	28	29	26		
Simple model ^a	ref	1.19 (0.62-2.27)	1.42 (0.74-2.71)	0.91 (0.47-1.77)	0.86	0.98 (0.78-1.24)
Full model ^b	ref	1.48 (0.75-2.93)	1.99 (0.97-4.09)	1.46 (0.68-3.14)	0.28	1.16 (0.89-1.53)

Abbreviations: TT, total testosterone; FT, free testosterone; SHBG, sex hormone-binding globulin; OR, odds ratio; CI, confidence interval; ref, reference.

^a Adjusted for age at infection, sex, and race.

^b Additionally adjusted for Townsend deprivation index, body mass index, smoking status, alcohol drinking, physical activity, menopause status, and hormone replacement treatment.

^c SD was the standard deviation of log-transformed hormone levels: 0.46 for TT, 0.59 for FT, and 0.51 for SHBG.

325 **Figure Legend**

326 **Figure 1.** Forest plots of stratified analysis for the associations of serum total
327 testosterone, free testosterone, and sex hormone-binding globulin levels with
328 COVID-19 mortality.

Subgroup	Male		OR per 1-SD increment (95% CI)	P-interaction	Female		OR per 1-SD increment (95% CI)	P-interaction
	Total N	N cases			Total N	N cases		
TT								
Age at infection (years)				0.33				0.92
<70	322	34	1.72 (1.07-2.76)		339	22	1.31 (0.81-2.12)	
≥70	355	160	0.92 (0.74-1.14)		201	74	1.11 (0.80-1.53)	
BMI (kg/m²)				0.57				0.89
<30	466	125	0.95 (0.75-1.21)		369	54	1.30 (0.87-1.93)	
≥30	211	69	1.31 (0.92-1.86)		171	42	1.13 (0.76-1.69)	
Physical activity (MET-hour/week)				0.16				0.99
Below	385	116	1.21 (0.93-1.58)		347	69	1.08 (0.79-1.47)	
Above	292	78	0.88 (0.65-1.18)		193	27	1.07 (0.61-1.87)	
Smoking status				0.73				0.55
Never	288	66	1.13 (0.79-1.62)		314	51	0.99 (0.69-1.43)	
Ever	381	126	1.07 (0.84-1.36)		223	45	1.18 (0.79-1.77)	
FT								
Age at infection (years)				0.77				0.85
<70	289	29	1.22 (0.73-2.04)		304	22	1.20 (0.71-2.02)	
≥70	330	149	0.88 (0.69-1.11)		182	64	1.20 (0.82-1.74)	
BMI (kg/m²)				0.04				0.49
<30	432	120	0.80 (0.62-1.05)		332	48	1.35 (0.85-2.13)	
≥30	187	58	1.31 (0.90-1.91)		154	38	1.12 (0.70-1.78)	
Physical activity (MET-hour/week)				0.44				0.94
Below	352	105	1.13 (0.86-1.48)		313	63	1.06 (0.76-1.49)	
Above	267	73	0.75 (0.53-1.06)		173	23	1.08 (0.56-2.10)	
Smoking status				0.41				0.94
Never	262	60	1.21 (0.83-1.76)		286	47	1.01 (0.69-1.50)	
Ever	349	116	0.86 (0.66-1.12)		197	39	1.14 (0.71-1.82)	
SHBG								
Age at infection (years)				0.44				0.73
<70	290	29	1.41 (0.89-2.22)		351	27	1.29 (0.77-2.16)	
≥70	331	150	1.02 (0.78-1.32)		223	84	1.06 (0.75-1.50)	
BMI (kg/m²)				0.17				0.61
<30	433	121	1.19 (0.89-1.59)		396	68	1.14 (0.79-1.66)	
≥30	188	58	1.01 (0.69-1.50)		178	43	1.20 (0.73-1.99)	
Physical activity (MET-hour/week)				0.44				0.60
Below	354	106	1.16 (0.86-1.55)		369	80	1.10 (0.79-1.51)	
Above	267	73	1.03 (0.71-1.48)		205	31	1.34 (0.73-2.48)	
Smoking status				0.76				0.20
Never	264	61	0.94 (0.63-1.39)		340	58	1.09 (0.76-1.57)	
Ever	349	116	1.24 (0.93-1.65)		229	53	1.36 (0.87-2.10)	
			0.5 1 1.5 2 2.5 3					0.5 1 1.5 2 2.5